Dear Editor,

The recent report on an H1N1-infected patient in intensive care unit (ICU) is an interesting report.\[[@ref1]\] Kumar *et al*.\[[@ref1]\] reported that "Fever and breathlessness were the main presenting complaints"\[[@ref1]\] and "Serum procalcitonin (PCT) level estimation is useful in determining outcome".

Of interest, the clinical finding of the ICU patients in this case series is not different from other reports in any groups of patients. However, 100% of the two main complaints (fever and breathlessness) seem extremely high compared to the Indian multi-center data.\[[@ref2]\] In addition, a very high death rate in this report might reflect the severity of the disease, with some possible relationship with the clinico-geographical determinant, the delay in case presentation and admission into ICU, or the limitation of the advanced medical care service in the studied ICU. In Thailand, the problem of severe H1N1 infection can also be seen. The high mortality rate can be seen in a report from a rural hospital among the patients with co-infection, underlying medical conditions, or delayed presentation.\[[@ref3]\] Indeed, a global report also showed that the death rate of the epidemic H1N1 infection was not different from that of classical influenza.\[[@ref4]\]

Focusing on the serum PCT, there are some reports on possible clinical usefulness in the management of H1N1-infected cases.\[[@ref5][@ref6]\] However, the important consideration is the lack of the cost-effectiveness evaluation of this new laboratory test. To get this information, the cost of serum PCT test and the diagnostic properties (true positivity, true negativity, and accuracy) in each setting should be determined. The simple cost per an accurate diagnosis can be calculated and can be further used as a rough indicator for cost-effectiveness of the test.
